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ERK1/2The calcium-sensing receptor (CaSR) couples to signalling pathways via intracellular loops 2 and 3,
and the C-terminus. However, the requirements for signalling are largely undeﬁned. We investi-
gated the impacts of selected point mutations in iL-2 (F706A) and iL-3 (L797A and E803A), and a
truncation of the C-terminus (R866X) on extracellular Ca2+ (Ca2+o )-stimulated phosphatidylinositol-
speciﬁc phospholipase-C (PI-PLC) and various other signalling responses. CaSR-mediated activation
of PI-PLC was markedly attenuated in all four mutants and similar suppressions were observed for
Ca2+o -stimulated ERK1/2 phosphorylation. Ca2+o -stimulated intracellular Ca2+ (Ca2+i ) mobilization, how-
ever, was relatively preserved for the iL-2 and iL-3 mutants and suppression of adenylyl cyclase was
unaffected by either E803A or R866X. The CaSR selects for speciﬁc signalling pathways via the proximal
C-terminus and key residues in iL-2, iL-3.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The extracellular Ca2+-sensing receptor (CaSR) belongs to a
nutrient-sensing receptor subgroup of G-protein-coupled receptor
(GPCR) Class C (reviews: [1,2]). It conforms to a domain-based
structure that includes an N-terminus extracellular Venus FlyTrap
(VFT) domain linked to a canonical heptahelical signalling domain
via an intervening Cysteine-rich domain (reviews: [3,4]). An
extended intracellular C-terminal domain of 215 residues provides
interactions between the receptor, the cytoskeleton, and some of
its key signalling partners (review: [5]). The CaSR acts as a key
component of the calciostat that provides feedback regulation of
parathyroid hormone secretion (review: [6]). In addition, it is
expressed widely in tissues including the kidney, gastro-intestinal
tract, bone, brain, and lung in which it plays quite different roles.These include contributions to the control of epithelial transport,
hormone secretion, and even cell fate (review: [7]).
The CaSR binds and responds to various endogenous ligands
including not only extracellular Ca2+ (Ca2+o ) and Mg2+ but also
organic multivalent cations such as spermine, which acts as an allo-
steric agonist [8] and L-amino acids, which act as positive modula-
tors (review: [9]) that bind in the receptor’s VFT domain [10]. In
addition, the CaSR is activated by synthetic modulators (calcimimet-
ics) including the clinically effective phenylalkylamine cinacalcet,
which bind in the receptor’s heptahelical domain [11].
The ﬁnding that the receptor has multiple ligand binding sites
and responds to multiple sensing modalities has led us to investi-
gate whether the receptor employs ligand-biased signalling to con-
trol function in its diverse cellular contexts. Thus far, these studies
have demonstrated that the CaSR exhibits pronounced ligand-
biased signalling via pathways coupled to intracellular Ca2+
(Ca2+i ) mobilization, ERK1/2 phosphorylation and membrane rufﬂing
[12], and that mutations associated with disturbed CaSR function
in vivo perturb the normal balance between different signalling
pathways with respect to the potencies and even efﬁcacies of Ca2+o
and other activators [13,14]. The ﬁndings indicate that signalling
bias is an important property of the receptor that can explain
Table 1
Sequences of forward and reverse primers used to generate the CaSR point mutations
tested in the study. The mutated codon is underlined.
Mutant Primers used in site-directed mutagenesis reactions
F706A F: 50-CCAACCGTGTCCTCCTGGTGGCTGAGGCCAAGAT-30
R: 50-TGGGGATCTTGGCCTCAGCCACCAGGAGGACA-30
L797A F: 50-TTCAAGTCCCGGAAGGGCGCCGGAGAACTTCAATGAA-30
R: 50-AAGTTCTCCGGCGCCTTCCGGGACTTGAAGGCAAA-30
E803A F: 50-GCCGGAGAACTTCAATGCAGCCAAGTTCATCACCTTCAG-30
R: 50-GTGATGAACTTGGCTGCATTGAAGTTCTCCGGCAGCTTC-30
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the patterns of disease arising from speciﬁc disease-related
mutations.
Signalling bias arises from the adoption of speciﬁc ligand-bound
receptor conformations that select between signalling pathways,
pointing to the existence of distinct molecular requirements for
the activation of different G-proteins and their downstream signal-
ling pathways. In response to stimulation by its principal physio-
logical agonist, Ca2+o , for example, the CaSR couples to various
intracellular signalling responses including Gq/11-mediated activa-
tion of PI-PLC, Ca2+i mobilization, Gi/o-mediated inhibition of aden-
ylyl cyclase, and thus suppression of intracellular cAMP levels
(review: [6]), as well as the phosphorylation of various protein
kinases including the MAP kinase ERK1/2 (pERK1/2) [15,16].
In the present study, we set out to investigate whether it is pos-
sible to deﬁne distinct subsets of molecular requirements for the
Ca2+o -stimulated activation of Gq/11, Gi/o and ERK1/2 phosphorylation,
taking advantage of previous work on the molecular requirements of
Ca2+o -stimulated PI-PLC activation by the bovine CaSR [17], which
exhibits 93% amino acid identity with the human CaSR (hCaSR). This
work identiﬁed the conserved residue F707 (hCaSR residue F706) in
iL-2, and three mutants homologous to hCaSR L797A, F801A and
E803A, all of which exhibited marked attenuations in their Ca2+o -
stimulated PI-PLC responses [17]. Furthermore, truncation of the
proximal C-terminus beyond hCaSR residue S865, by the introduc-
tion of a premature stop codon R866X, abolished PI-PLC signalling
[18,19].
Thus, we investigated the impacts of four human CaSR mutants
on Ca2+o -stimulated signalling responses including: PI-PLC as
reported by IP1 accumulation; Ca2+i mobilization; pERK1/2; and sup-
pression of adenylyl cyclase. The results indicate that there are dis-
tinct G-protein coupling requirements for CaSR-mediated Gq/11 and
Gi/o activation and that these differences are important for signalling
pathway selection in response to elevated Ca2+o . Since distinct ligands
exhibit signiﬁcant differences in CaSR-mediated signalling pathway
selection the current ﬁndings would also appear to provide insights
into the nature of biased signalling responses.
2. Materials and methods
2.1. Construction of mutant receptors
The wild-type (WT) human CaSR cDNA (cassette version, [20])
cloned between the Kpn I and Xba I sites of pcDNA3.1 (+)
{pcDNA3.1 (+)-WTCaSR} was a kind gift from Dr. Mei Bai and Prof.
Edward Brown (Endocrine-Hypertension Division and Membrane
Biology Program, Brigham and Women’s Hospital, Boston, MA,
USA). All mutants were generated in pcDNA3.1(+)-WTCaSR and/
or pcDNA3.1(+)-WTCaSR(FLAG) plasmid, which contains the FLAG
epitope DYKDDDDK between residues 371 and 372; insertion of
the FLAG epitope at this position has been shown previously to
have no impact on receptor function [21]. The Quikchange II site-
directed mutagenesis protocol was used to introduce the point
mutations F706A, L797A and E803A. Brieﬂy, pairs of complemen-
tary or overlapping primers (30–40 bases) were designed to
encode the required mutation with ﬂanking wild-type sequences
of around 15–20 bases. The template DNA was ampliﬁed for 18
cycles with Pfu Ultra II HS DNA polymerase (Agilent Technologies,
USA). Following digestion with Dpn I, ampliﬁed DNA was trans-
formed into DH5a Escherichia coli cells. Sequences of forward and
reverse primers used to generate the required point mutations
are shown in Table 1.
A truncation mutant, R866X, which introduces a premature
stop codon after S865 in the proximal C-terminus, was also gener-
ated. Brieﬂy, the template cDNA was ampliﬁed by PCR using aforward primer designed to bind to the ﬁrst 22 nucleotides of the
CaSR cDNA with a 50 Kpn I site (50-CAG TAT GGT ACC ATG GCA
TTT TAT AGC TGC TGC T) and a reverse primer (50-TAGACT TCT
AGA TTA GGA TGG CTT GAA GAG AAT GAT) that introduced a stop
codon (TAA) at residue 866 (underlined) followed by a 30 Xba I site.
The PCR product obtained using the wild-type CaSR as the tem-
plate was digested with Kpn I and Xba I and ligated into the multi-
ple cloning site of puriﬁed pcDNA3.1(+) that had been pre-digested
using these enzymes. The identities of all completed mutants were
conﬁrmed by DNA sequencing (Australian Genome Research Facil-
ity, Sydney, NSW, Australia).
2.2. Cell culture and transfection
HEK-293 cells were cultured in Dulbecco’s modiﬁed Eagle med-
ium (DMEM) supplemented with 10% FBS, 25 Units/ml Penicillin
and 25 lg/ml of Streptomycin, and maintained at 37 C in a humid-
iﬁed 5% CO2 incubator. When cells had reached 85–95% conﬂuency
they were transfected with XtremeGENE HP transfection reagent
(Roche, Germany). Brieﬂy, 0.5–1 lg samples of WT or mutant
DNA in 1–2 ll of water and 3 ll of transfection reagent were
diluted with 100 ll of DMEM and allowed to complex at RT for
15 min. The transfection solution was added to the cell cultures
to a ﬁnal concentration of 9.1% (v/v). In all experimental series,
identical DNA concentrations were used for all constructs tested
(i.e., WT and all four mutants). For cAMP measurements, 0.5 lg
samples of cAMP reporter construct DNA were added along with
the WT or mutant DNA to the transfection solutions.2.3. Quantitation of total and surface receptor expression
HEK-293 cells were cultured in 96-well poly-D-lysine coated
plates and transiently transfected for 48 h with either the wild-
type CaSR or one of several mutant CaSRs. After transfection, cell
samples, at an approximate density of 100% (4  104 cells well1),
were washed once with TBS-T (0.05M Tris, 0.15 M NaCl, 0.05% (v/v)
Tween-20, pH 7.4) and ﬁxed for 15 min on ice with either 4% (w/v)
paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2-
HPO4, 1.8 mM KH2PO4, pH 7.4) to determine surface expression, or
methanol, to determine total cell expression. All subsequent steps
were performed at room temperature. After washing once with
TBS-T, ﬁxed cell samples were incubated with 1% (w/v) skim milk
solution in TBS-T for 1 h and then incubated with monoclonal anti-
FLAG M2 horse-radish peroxidase (HRP)-conjugated antibody
(Sigma Aldrich #A8592) diluted 1:5000 in TBS-T for 1 h. The wells
were then washed three times with PBS and incubated with the
HRP substrate, 3,30,5,50 tetramethylbenzidine liquid substrate solu-
tion (Sigma Aldrich cat. #T0440) in the dark for 12 min. Enzyme
reactions were stopped by the addition of equal volumes of 1 M
HCl. Supernatant samples were transferred to new 96-well plates
and A450 values were obtained using a Perkin-Elmer EnVision
2103 multilabel counter (software version 1.08, Perkin Elmer,
USA).
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monophosphate (IP1)
HEK-293 cells were cultured in 6-well plates and transfected at
90% conﬂuency for 24 h. Cell samples (from ca. 1.2  106 cells)
were detached with 0.2 ml lots of 0.25% trypsin–EDTA, followed
by the addition of 5–10 ml DMEM (10% FBS; 25 Units/ml Penicillin,
25 lg/ml Streptomycin) and centrifugation (210g, 3 min). Cell
pellets were re-suspended in 1.2 ml of DMEM (10% FBS, 25 Units/
ml Penicillin, 25 lg/ml Streptomycin), and 30 ll samples of cell
suspensions were aliquoted into 384 well Optiplates (Perkin Elmer,
USA) and cultured for 24 h. On the day of the experiment, the med-
ium was removed from each well and the cells were incubated for
30 min in 14 ll lots of stimulation buffer that contained 146 mM
NaCl, 4.2 mM KCl, 5.5 mM glucose, 0.5 mM MgCl2, 10 mM HEPES
(pH 7.4), and 50 mM LiCl to suppress IP1 breakdown. IP1 was
detected by overnight incubation with 3 ll/well of anti-IP1 cryp-
tate Tb conjugated antibody (diluted in 1  lysis buffer according
to the manufacturer’s instructions) and 3 ll/well of similarly pre-
pared IP1-d2 conjugate. Time-resolved FRET was measured on a
Perkin-Elmer EnVision 2103 multilabel counter with excitation at
320 nm and emission at 615 and 665 nm. The F615/F665 emission
ratio was used as a measure of IP1.
2.5. Cytoplasmic Ca2+ mobilization ﬂuorescence assay
Microﬂuorimetry to measure changes in Ca2+i was performed as
described previously [22]. All Ca2+ solutions were prepared in phys-
iological saline solution (PSS) that contained 125 mM NaCl, 4 mM
KCl, 0.1% (w/v) D-Glucose, 1 mM MgCl2, 20 mM HEPES (pH 7.45
adjusted with NaOH). Brieﬂy, HEK-293 cells that had been cultured
on 15 mm sterile glass coverslips in 24-well plates were transfected
with either the WTCaSR or one of several CaSR mutants for 48 h.
After transfection, the cells were rinsed with PSS supplemented with
0.8 mM NaH2PO4 and 0.1% (w/v) bovine serum albumin (BSA) and
then incubated with this solution containing 5 lM Fura 2-AM for
90–120 min at 37 C in a humidiﬁed 5% CO2 incubator in the dark.
The cells were washed once and stored in loading solution until
required for microscopy.
For microﬂuorimetry, cells on coverslips that had been loaded
with Fura 2-AM were placed in a closed bathing chamber and
mounted onto the stage of a Zeiss Axiovert 200 M ﬂuorescence
microscope for live cell imaging and perifused with PSS containing
various Ca2+o concentrations. Fluorescence images were obtained
using a 63 objective following excitation from a Lambda DG-4
Xenon light source (Sutter) at alternating wavelengths of 340 and
380 nm with an exposure time of 0.5 s. Images were collected via
an emission ﬁlter centred on 510 nm using an Axiocam HSm digital
camera (Zeiss) and downloaded using Slidebook software (Intelli-
gent Imaging Solutions; Colorado, USA). F340/F380 excitation ratio
data were used as measures of Ca2+i concentration and integrated
to assess Ca2+o concentration-dependent responses. The data were
expressed as integrated ﬂuorescence response units (IFRUs) and nor-
malised with respect to the responses for control Ca2+o (0.5 mM) as
required.
2.6. AlphaScreen ERK1/2 phosphorylation assay
Receptor-mediated ERK1/2 phosphorylation was quantiﬁed
using AlphaScreen SureFire assays (Perkin Elmer, USA). HEK-293
cells were seeded onto poly-D-lysine coated 96-well plates and
transfected with the WTCaSR or one of the CaSR mutants for 48 h
as needed. After transfection, the cells were pre-incubated at
37 C in a humidiﬁed 5% CO2 incubator for 4–14 h in DMEM/0.2%
BSA (no FBS) that contained 1.5 mM Ca2+. Serum starvation
between these time intervals had the effect of loweringbackground levels of pERK1/2 due, presumably, to the withdrawal
of serum growth factors. The medium was then removed from
each well and after washing with PSS (0.2 ml), the cells were
pre-incubated in PSS that contained 0.2 mM Ca2+ (90 ll) for
30 min. The wells containing adherent cells were then activated
by the addition of 10 ll lots of PSS that contained 10 ﬁnal Ca2+
concentration for 10 min at 37 C. The supernatants were then
removed and the cells were lysed by the addition of 50 ll lots of
AlphaScreen Lysis Buffer (Perkin-Elmer) with shaking at 150 rpm
for 10–15 min at RT. Samples of lysates (5 ll lots) were then
transferred to 384-well Optiplates (Perkin-Elmer) and incubated
overnight with acceptor and donor beads as speciﬁed in the man-
ufacturer’s instructions. Chemiluminescence counts were quanti-
ﬁed using the AlphaScreen protocol in a Perkin-Elmer EnVision
2103 multilabel counter. To generate Ca2+o concentration–response
curves, raw data were expressed as fold-changes with respect to
the behaviour of the WT CaSR at baseline Ca2+o (0.5 mM).
2.7. Intracellular cAMP assay
Microﬂuorimetry was performed to detect changes in intracel-
lular cAMP levels as described previously [22]. Brieﬂy, HEK-293
cells were seeded onto sterile glass coverslips in 24-well plates.
The cells were then transfected with either the WTCaSR, or one
of several mutant CaSR constructs, and co-transfected with the
cAMP ﬂuorescence resonance energy transfer reporter construct:
CFP-EPAC-YFP-YFP (the kind gift of Dr. Kees Jalink, Netherlands
Cancer Institute [23]). After 48 h, the medium was removed from
each well and the cells were incubated with 0.5 mM Ca2+ in PSS
for 15 min at 37 C. The coverslips were then transferred individu-
ally to a closed bathing chamber and placed in the light path of the
Zeiss Axiovert 200 M microscope described above. The cells were
then exposed to PSS that contained 1 lM Forskolin for 15 min to
elevate intracellular cAMP levels in the presence of baseline Ca2+o
(0.5 mM) followed by stepwise increments in Ca2+o (0.5–10 mM) for
7 min each. In control experiments, 7 min was found to be an appro-
priate time for the adoption of a new steady-state level of cAMP.
Excitation was performed at a constant wavelength of 436 nm and
emission was performed at alternating wavelengths of 488 and
528 nm for intervals of 0.5 s corresponding to FCFP and FYFP, respec-
tively. Images were collected using the Axiocam HSm digital camera
described above in Section 2.5 and computed by Slidebook software
as the FCFP/FYFP emission ratio as a measure of intracellular cAMP
levels. The emission ratios arising from the last one-minute intervals
of exposure were averaged and after background subtraction
(0.5 mM Ca2+o control) were expressed as percentages of the Forskolin-
stimulated emission ratio to generate Ca2+o concentration–response
curves.
2.8. Curve ﬁtting and statistical analysis
The data are expressed routinely as means ± S.E.M. For Ca2+i
mobilization experiments, Ca2+o concentration–response data were
obtained by integrating the F340/F380 excitation ratio data obtained
in response to each Ca2+o concentration as described previously
[22]. Concentration–response data for IP1 accumulation, Ca2+i mobi-
lization and pERK1/2 were ﬁtted to the following form of the Hill
equation:
R ¼ dþ ða dÞCb=ðeb þ CbÞ ð1Þ
where a = maximal response (Emax); b = Hill co-efﬁcient; e = half
maximal effective concentration (EC50); d = minimum response.
Concentration–response data for suppression of intracellular cAMP
levels were ﬁtted using the following equation:
R ¼ a ða dÞCb=ðeb þ CbÞ ð2Þ
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Eq. (1).
Statistical analyses were performed using analysis of variance
(ANOVA) in GraphPad Prism 5. Statistical signiﬁcance was accepted
at P < 0.05. Log transformations of EC50 or IC50 values were used to
assess the statistical signiﬁcance of differences in Ca2+o -sensitivity.
3. Results
3.1. Construction and expression of PLC signalling defective CaSR
mutants
To assess the impacts of the PI-PLC-signalling defective mutants
on various CaSR-mediated signalling pathways, we generated three
alanine mutants in CaSR iL-2 (F706A) and iL-3 (L797A and E803A)
as well as a C-terminus truncation mutant, R866X, which retains
only the three membrane-proximal residues (863-KPS-865) of
the normal 216 residue C-terminus (Fig. 1A). The constructs were
transiently transfected into HEK-293 cells to assess expression
and function. Levels of total and cell surface expression for all fourA
Fig. 1. PI-PLC signalling-defective mutants in iL-2, iL-3 and the C-terminal region, and th
black in both iL-2 (F706) and iL-3 (L797 and E803). A mutation (R866X) that truncates th
reported previously to impair PI-PLC signalling [17,19]. (B) Effects of iL point mutations
cells were transiently transfected with FLAG-tagged WT or mutant constructs, and then
expression (j) as described in the Section 2. Results obtained in HEK-293 cells transfec
mutants were normalised to the level of total WTCaSR expression. The results were obt
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accumulation and a maximally effective Ca2+o of 20 mM; a 4-fold
increase in IP1 was observed with respect to the baseline response
at 0.5 mM Ca2+o .
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those described previously [17,19].
3.3. The impacts of iL-2, iL-3 and C-terminus truncation mutants on
CaSR-mediated Ca2+i mobilization
We next investigated the impacts of the mutants on Ca2+i mobi-
lization in single Fura 2- loaded HEK-293 cells by microﬂuorimetry.
TheWTCaSR induced Ca2+o -dependent Ca2+i mobilization with an EC50
for Ca2+o of 2.9 ± 0.2 mM and an Emax of 13.8 ± 0.4 IFRU, and the
C-terminus truncation mutant R866X abolished Ca2+o -dependent
Ca2+i mobilization (Fig. 2B). In the cases of all three iL point mutants
studied, however, Ca2+i mobilization was relatively preserved. Thus,
there were only approximately 50% reductions in Emax values (all
P < 0.01) and the EC50 values for Ca2+o were similar to and not signif-
icantly different from WT (P > 0.1 in all cases; Fig. 2B). In particular,
the EC50 values for Ca2+o in the case of the iL-2 mutant F706A was
5.3 ± 0.6 mM and in the cases of the iL-3 mutants L797A and
E803A were 6.8 ± 1.4 and 3.0 ± 0.6 mM respectively. Thus, the
impacts of the iL-2 and iL-3 mutants were less marked on Ca2+i mobi-
lization than on IP1 accumulation, although Ca2+i mobilization was
abolished in HEK-293 cells that were transiently transfected with
R866X.
3.4. The impacts of iL-2, iL-3 and C-terminus truncation mutants on
CaSR-mediated phosphorylation of ERK1/2
The impacts of the mutants on Ca2+o -stimulated ERK1/2 phosphor-
ylation (pERK1/2) were investigated using a dual antibody Alpha-
screen assay as described in the Section 2. In HEK-293 cells
expressing the WTCaSR, elevated Ca2+o induced concentration-depen-
dent increases in pERK1/2 to a maximum 10–12-fold above the base-
line level observed at a Ca2+o of 0.5 mM. The EC50 for Ca2+o was
2.4 ± 0.3 mM (Fig. 3). The C-terminus truncation mutant did not sup-
port Ca2+o -stimulated pERK1/2 at concentrations up to 10 mM. In
addition, the three point mutations F706A, L797A and E803A mark-
edly suppressed the Emax values by P90% with respect to the
WTCaSR (P < 0.001 in all three cases). The results indicate that
Ca2+o -stimulated CaSR-mediated pERK1/2 is critically dependent on
residues in iL-2 and iL-3 that are required for PI-PLC activation along
with residues that lie to the C-terminus side of S865.Extracellular [Ca2+] (mM)
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Fig. 3. Impact of CaSR mutants on Ca2+o -stimulated pERK1/2. ERK1/2 phosphorylation
levels in cell lysates prepared from HEK-293 cells that had been ﬁrst transfected with
the WTCaSR (d), or one of several mutants including R866X (s), F706A (h), L797A
(4) or E803A (5), and then exposed to various Ca2+o concentrations for 10 min, were
quantiﬁed using the AlphaScreen pERK1/2 assay as described in the Section 2. The
results are expressed relative to HEK-293 cells transfected with WTCaSR and exposed
to baseline Ca2+o (0.5 mM). The results were obtained in 3–8 independent
experiments.3.5. The impacts of iL-2, iL-3 and C-terminus truncation mutants on
CaSR-mediated suppression of adenylyl cyclase as reported by cAMP
levels
We next examined the impacts of the iL-2, iL-3 and C-terminus
truncation mutants on CaSR- mediated suppression of adenylyl
cyclase as reported by cAMP levels measured in individual
cells by microﬂuorimetry. Initial experiments demonstrated that
Ca2+o -dependent suppression of intracellular cAMP levels but not
Ca2+o -dependent Ca2+i mobilization was abolished after overnight
pre-exposure to pertussis toxin (300 ng mL1) and was insensitive
to the phosphodiesterase inhibitor IBMX (0.2 mM), thereby demon-
strating that Gi/o-mediated inhibition of adenylyl cyclase was the
major determinant of Ca2+o -stimulated suppression of cAMP levels
in these experiments (not shown). HEK-293 cells were transiently
co-transfected with a cAMP reporter construct and one of the four
CaSR mutants, and studied by microﬂuorimetry as described in the
Methods section. Samples of transfected cells were exposed to
1 lM forskolin to elevate intracellular cAMP levels followed by
step-wise increments in Ca2+o from 0.5 to 10 mM.
HEK-293 cells transfected with the WTCaSR exhibited Ca2+o -
dependent suppression of 1 lM forskolin-stimulated cAMP levels
with an EC50 for Ca2+o of 1.7 ± 0.2 mM and a maximal 60% suppres-
sion of cAMP levels (Fig. 4). Two of the point mutations, F706A
and L797A abolished Ca2+o -dependent cAMP suppression (Fig. 4).
However, surprisingly, the Ca2+o -stimulated inhibitory responses
were maintained in HEK-293 cells transfected with either the iL-3
point mutation E803A or the C-terminus truncation mutant R866X.
In the case of R866X, there was no apparent change in the EC50 for
Ca2+o . In the case of E803A, an apparent drop in EC50 for Ca2+o from
1.7 ± 0.2 to 0.9 ± 0.1 mM (Fig. 4) was not statistically signiﬁcant
(P = 0.07). The ﬁndings demonstrate that the molecular require-
ments for Ca2+o -stimulated CaSR-mediated inhibition of cAMP levels
are clearly distinct from those required for the control of PI-PLC, Ca2+i
mobilization and pERK1/2 and provide new insights into the nature of
biased signalling.
4. Discussion
Within GPCR class C there is a sub-group of nutrient-sensing
receptors that respond to both macronutrients, such as L-amino
acids, as well as micronutrients, such as Ca2+ ions (review: [2]).
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diverse physiological roles. These include the feedback control of
calcium homeostasis via cell-based mechanisms in the parathy-
roid, renal thick ascending limb, and bone [24], the modulation
of tissue development and cell fate [7], and L-amino acid sensing
mechanisms [25] and various other functions in the gastro-intesti-
nal tract (review: [26]). This surprising pluripotency requires pre-
cise control over a large number of receptor-coupled signalling
pathways, and, thus, mechanisms by which the receptor can select
between pathways.
In the present study, we focused on Ca2+o -stimulated control of
four key CaSR-mediated signalling pathways: PI-PLC, Ca2+i mobiliza-
tion; ERK1/2 phosphorylation; and suppression of adenylyl cyclase,
using key point mutants of CaSR iL-2 and iL-3, as well as a truncation
mutant of the proximal C-terminus to assess the roles of these struc-
tural components in the selection of distinct signalling pathways.
We used transient expression of the ﬁve different CaSR constructs
in the present study to ensure that the cell context was identical
in all cases. None of the mutants impaired either total or surface
expression of the receptor, and all of them exhibited marked sup-
pression of Ca2+o -stimulated PI-PLC (Figs. 1B and 2A) as reported pre-
viously [17,19]. Strikingly, we found that the C-terminal-proximal
region is required for the activation of PI-PLC, Ca2+i mobilization
and pERK1/2 but not for Gi/o-dependent inhibition of adenylyl
cyclase, as reported by the suppression of forskolin-stimulated ele-
vations in cAMP levels. In addition, we observed important differ-
ences in the roles of key iL-2 and iL-3 residues in supporting
signalling by distinct pathways. Thus, although F706 and L797 were
required for both Gq/11- and Gi/o-dependent signalling, E803 was
only required for Gq/11 and not Gi/o-dependent signalling. The results
indicate that distinct residues in these key intracellular regions of
the CaSR are required by the mechanisms that engage speciﬁc path-
ways in response to Ca2+o -stimulation. See Table 2 for a summary of
the outcomes.
All mutants markedly impaired Ca2+o -stimulated pERK1/2 as well
as PI-PLC suggesting the existence of a common signalling mecha-
nism downstream of Gq/11. Ca2+o -stimulated CaSR-mediated pERK1/2
was nearly abolished by the PI-PLC inhibitor, U73122, and also mark-
edly suppressed following pre-treatment with pertussis toxin, which
disables Gi/o [15,27]. Thus, both Gq/11-stimulated PI-PLC and Gi/o
appear to be required for pERK1/2.
Surprisingly, there were notably lesser impacts of the three
point mutants on Ca2+i mobilization when compared with their
effects on IP1 accumulation (Fig. 2B) and only the C-terminus trunca-
tion mutant R866X abolished Ca2+o -stimulated Ca2+i mobilization.
Thus, the results suggest only a partial dependence of CaSR-medi-
ated Ca2+i mobilization on PI-PLC. Other pathways that may contrib-
ute to CaSR-mediated Ca2+i mobilization include a G12/13-coupled
pathway dependent on a Rho and Filamin-A-dependent interaction
with the receptor’s C-terminus [28]. Such a mechanism could
explain how the C-terminal truncation mutant R866X abolished
Ca2+i mobilization. G12 has also been reported to activate proteinTable 2
Impacts of mutations on Ca2+o -stimulated CaSR signalling. The inhibitory effects of the
four mutants are summarized with respect to the wild-type CaSR for PI-PLC, pERK1/2,
Ca2+i mobilization, and inhibition of adenylyl cyclase (AC). ‘+++’, indicates a WT
response; ‘++’ and ‘ + ’ indicate moderately reduced or markedly reduced responses;
‘’ indicates abolition of the response.
WT F706 L797 E803 R866X
PI-PLC +++ + + + +
Ca2+i mobilisation +++ ++ ++ ++ –
pERK1/2 +++ + + + +
Inhibition of AC +++ – – +++ +++phosphatase 2A [29], an enzyme that supports Ca2+o -stimulated
dephosphorylation of CaSR residue T888 and, in turn, promotes sta-
ble elevations in Ca2+i [30].
Preliminary experiments investigating the effects of pre-
treatment with pertussis toxin and of acute exposure to the
broad-spectrum phosphodiesterase (PDE) inhibitor IBMX demon-
strated that the suppressive effect of Ca2+o on forskolin-induced ele-
vations in cAMP levels was dependent on Gi/o-mediated inhibition of
adenylyl cyclase and not PDE. Thus, the ﬁnding that F706A (iL-2) and
L797A (iL-3) were resistant to Ca2+o -stimulated suppression of cAMP
is consistent with the idea that both these residues are required
for CaSR-mediated coupling to Gi/o as well as Gq/11. However
Ca2+o -stimulated suppression of cAMP levels was retained at appar-
ently WT levels in the cases of the point mutant E803A (iL-3) and
the C-terminus truncation mutant R866X, demonstrating the
existence of distinct requirements for the activation of PI-PLC and
inhibition of adenylyl cyclase. In addition, the ﬁnding that R866X
abolished Ca2+o -stimulated Ca2+i mobilization but exhibited WT levels
of Ca2+o -stimulated suppression of cAMP appears to exclude a role for
Ca2+i -dependent inhibition of adenylyl cyclase in the present experi-
ments in which forskolin was used to elevate cAMP levels, distinct
from that reported previously for CaSR-expressing HEK-293 cells in
which they were elevated by prostaglandin E2 or isoproterenol [31].
The ﬁnding that CaSR-mediated coupling to the control of
PI-PLC and adenylyl cyclase is dependent on distinct residues is
consistent with ﬁndings on the signalling requirements of another
class C GPCR, mGluR1, in which some iL-2 mutants, including
T695A, K697A and S702A, selectively disabled PI-PLC activation,
whereas others including P698A and the two residue deletion
C694-T695, selectively impaired cAMP accumulation [32].
Similarly, deletion of the mGluR1 C-terminus selectively abolished
Gq/11, but not Gi/o-dependent signalling [33] as observed in the
present study for the Ca2+o -stimulated CaSR (Fig. 4).
The C-terminus also plays important roles in coupling other
class C GPCRs to speciﬁc G-protein-dependent signalling pathways
[34]. For example, alternative splicing of mGluR-1 results in
distinct G-protein coupling proﬁles based on differences in
C-terminus sequences. Thus, mGluR-1a with a longer C-terminus
coupled efﬁciently to both Gq/11 and Gs, whereas mGluR-1b with
a shorter C-terminus coupled efﬁciently to Gq/11 but did not couple
to Gs [35]. Furthermore, deletion of the mGluR-1 C-terminus selec-
tively abolished Gq/11-dependent but not Gi/o-dependent signalling
[33].
It is notable in the present study that where one or more of the
iL-2, iL-3 or C-terminus mutants impaired CaSR-mediated stimula-
tion of PI-PLC, Ca2+i mobilization, ERK1/2 phosphorylation, and/or
inhibition of adenylyl cyclase, the primary effect was a reduction
in the maximal response (Emax) rather than an increase in the EC50
value for Ca2+o (see Figs. 2–4), as more commonly reported for muta-
tions in human kindreds with familial hypocalciuric hypercalcemia
(FHH) or neonatal severe primary hyperparathyroidism (NSHPT)
(reviews: [36–38]). The ﬁnding that Emax was reduced is consistent
with the idea that Ca2+o binding and Ca2+o -dependent changes in
receptor conformation were normal in the extracellular VFT and
Cys-rich domains, but that coupling of the activated receptor to its
signalling apparatus in the dimeric heptahelical domains was defec-
tive as a result of impaired binding of partner proteins including
G-proteins and enzymes.
In the present study we have identiﬁed CaSR residues in iL-2
and iL-3 as well as the proximal C-terminus that are required for
Ca2+o -stimulated signalling, and demonstrated the existence of dis-
tinct requirements for the activation of PI-PLC and Ca2+i mobilization,
and suppression of adenylyl cyclase. Further work is required to
properly deﬁne the requirements of Ca2+o -stimulated pathways
downstream of Gq/11, Gi/o and G12/13, and to assess the ligand-biased
signalling requirements of physiologically and pharmacologically
3346 M.A. Goolam et al. / FEBS Letters 588 (2014) 3340–3346important agonists including divalent cations such as Mg2+ and Sr2+
and organic polycations such as spermine, as well as modulators
including L-amino acids and cinacalcet.
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